A5033837903- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Esophageal Cancer Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer-related Molecular Pathways
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Virus-based gene therapy research
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Cancer, Lipids, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced Breast Cancer Therapies
- Immune cells in cancer
- Vitamin D Research Studies
- Peptidase Inhibition and Analysis
Roswell Park Comprehensive Cancer Center
2017-2025
Cancer Research Center
2024
The University of Texas Health Science Center at San Antonio
2015-2023
Alliance for Clinical Trials in Oncology
2021
Lenox Hill Hospital
2012-2013
University General Hospital Attikon
2012
National and Kapodistrian University of Athens
2012
Athens Naval & Veterans Hospital
2009-2010
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in United States. A major challenge treatment remains patients’ advanced disease at diagnosis. The NCCN Guidelines for Adenocarcinoma provides recommendations diagnosis, evaluation, treatment, follow-up patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities including targeted therapies, provide hope improving patient outcomes. Sections manuscript have been...
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas exocrine pancreas are intended to assist with clinical decision-making. These Insights important updates 2019 version guidelines, focusing on postoperative adjuvant treatment patients pancreatic cancers.
Abstract HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor activation and has activity -mutant tumours. SUMMIT is open-label, single-arm, multi-cohort, phase 2, ‘basket’ trial of neratinib patients solid tumours harbouring oncogenic somatic (ClinicalTrials.gov: NCT01953926). The primary objective the BTC cohort, which now complete, first response rate (ORR)...
Pelareorep is an intravenously delivered oncolytic reovirus that can induce a T-cell-inflamed phenotype in pancreatic ductal adenocarcinoma (PDAC). Tumor tissues from patients treated with pelareorep have shown replication, T-cell infiltration, and upregulation of PD-L1. We hypothesized combination pembrolizumab chemotherapy PDAC would be safe effective.A phase Ib single-arm study enrolled who progressed after first-line treatment. Patients received pelareorep, pembrolizumab, either...
Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, intraduodenal portion bile duct, and pancreatic duct), while periampullary may arise locations encompassing head pancreas, distal duodenum, or Vater. are rare gastrointestinal malignancies, prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, treatment modality received. Systemic therapy is used in all stages ampullary cancer, including neoadjuvant...
This research investigates the association between benzodiazepines (BZD) and cancer patient survival outcomes, pancreatic tumor microenvironment, cancer-associated fibroblast (CAF) signaling.Multivariate Cox regression modeling was used to retrospectively measure associations Roswell Park outcomes BZD prescription records. IHC, H&E, Masson's trichrome, RNAscope, RNA sequencing were evaluate impact of lorazepam (LOR) on murine PDAC microenvironment. ELISA qPCR determine BZDs IL6 expression or...
The tumor-suppressor p53 is commonly inactivated in colorectal cancer and pancreatic ductal adenocarcinoma, but existing treatment options for p53-mutant (p53
PURPOSE Metastatic pancreatic adenocarcinoma (mPC) remains a difficult-to-treat disease. Fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) is standard first-line therapy for mPC patients with favorable performance status good organ function. In phase I study, devimistat (CPI-613) in combination modified FFX (mFFX) was deemed safe exhibited promising efficacy mPC. METHODS The AVENGER 500 trial (ClinicalTrials.gov identifier: NCT03504423 ) global, randomized III conducted at 74 sites...
539 Background: Tinengotinib is a spectrum-selective multi-kinase inhibitor with unique FGFR-binding mechanism. It potently inhibits FGFR2 fusion/rearrangement and acquired resistant mutations in pre-clinical models early clinical studies cholangiocarcinoma (CCA). Here we present the preliminary efficacy safety of tinengotinib (TT-00420) phase II trial TT420C1206 (NCT04919642). Methods: Eligible patients (pts) advanced/metastatic CCA exhausting standard treatment options received 10 mg QD....
434 Background: Tinengotinib is a spectrum-selective multi-kinase inhibitor with unique binding properties to FGFR, potently inhibited FGFR2 fusion/rearrangement and acquired resistant mutations in pre-clinical models phase I trials that included cholangiocarcinoma (CCA) patients (pts). Here we present the efficacy safety of tinengotinib II clinical trial. Methods: Eligible pts advanced/metastatic CCA who had received ≥ 1 prior systemic chemotherapy therapy ECOG PS 0 or were treated 10 mg...
Oral squamous cell carcinoma (OSCC) is a deadly disease that comprises 60% of all head and neck cancers. The leaves the Neem tree (Azadirachta indica) have been used in traditional Ayurvedic medicine for centuries to treat numerous oral maladies are known significant anti-inflammatory properties. We hypothesize highly pure super critical CO2 leaf extract (SCNE) prevents initiation progression OSCC via downregulation intra-tumor pro-inflammatory pathways, which promote tumorigenesis. Hence,...
TPS153 Background: The clinical benefit of approved therapies in patients (pts) with metastatic colorectal cancer (mCRC) who progress on first- and second-line chemotherapy (FOLFOX FOLFIRI) is limited. In pts chemotherapy-refractory RAS wild type mCRC, antibodies targeting EGFR offer a monotherapy response rate approximately 20% progression-free survival (PFS) 4 months (Price 2014). HER2 validated target gastric breast cancers, amplification occurring ~3–5% mCRC. Tucatinib (TUC), recently...
Pancreatic ductal adenocarcinoma (PDAC) has been left behind in the evolution of personalized medicine. Predictive markers response to therapy are lacking PDAC despite various histological and transcriptional classification schemes. We report an artificial intelligence (AI) approach histologic feature examination that extracts a signature predictive disease-specific survival (DSS) patients with receiving adjuvant gemcitabine. demonstrate this AI-generated is associated outcomes following...
Abstract Background Nintedanib is a tyrosine kinase inhibitor with efficacy in bevacizumab-resistant colorectal cancer models. This phase I/II study evaluated the recommended II dose and of nintedanib capecitabine refractory metastatic cancer. Methods Key eligibility criteria included ECOG performance status 1 or lower. The primary endpoint was 18-week progression-free survival (PFS). A 1-sided binomial test (at α = .1) compared observed PFS historic control .25. Results Forty-two patients...
320 Background: Genomic profiling studies have reported somatic HER2 mutations in ~2–5% of biliary tract cancers (BTC). Clinical data from the SUMMIT study demonstrate that neratinib, a pan-HER irreversible tyrosine kinase inhibitor, has encouraging clinical activity multiple types HER2-mutant solid tumor malignancies. Methods: is multi-histology, open-label, phase II ‘basket’ neratinib patients with (ClinicalTrials.gov NCT01953926). Patients activating different histologies, including BTC,...
Despite the occurrence of HER2 amplification/overexpression (HER2+) in ~3% to 5% all patients with metastatic colorectal cancer (mCRC) and up ~10% RAS/BRAF wild-type mCRC, there are currently no FDA- or EMA-approved HER2-directed therapies for HER2+ mCRC. Patients mCRC who progress on early lines chemotherapy regimens receive limited clinical benefit from current standard-of-care treatments. Tucatinib is a highly selective, HER2-directed, tyrosine kinase inhibitor. The MOUNTAINEER trial...